OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC Takes Position in ProQR Therapeutics (NASDAQ:PRQR)

OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new position in shares of ProQR Therapeutics (NASDAQ:PRQR - Free Report) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 227,020 shares of the biopharmaceutical company's stock, valued at approximately $602,000. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC owned 0.28% of ProQR Therapeutics as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. Adage Capital Partners GP L.L.C. increased its holdings in ProQR Therapeutics by 164.9% in the fourth quarter. Adage Capital Partners GP L.L.C. now owns 9,602,280 shares of the biopharmaceutical company's stock valued at $25,446,000 after buying an additional 5,976,813 shares during the last quarter. Millennium Management LLC lifted its position in shares of ProQR Therapeutics by 1,864.4% during the 4th quarter. Millennium Management LLC now owns 2,827,280 shares of the biopharmaceutical company's stock valued at $7,492,000 after acquiring an additional 2,683,351 shares during the last quarter. Affinity Asset Advisors LLC acquired a new position in ProQR Therapeutics during the fourth quarter valued at $7,486,000. DAFNA Capital Management LLC raised its position in ProQR Therapeutics by 73.1% during the fourth quarter. DAFNA Capital Management LLC now owns 1,567,561 shares of the biopharmaceutical company's stock valued at $4,154,000 after buying an additional 661,979 shares during the period. Finally, Platinum Investment Management Ltd. purchased a new stake in shares of ProQR Therapeutics during the fourth quarter worth $4,076,000. 32.65% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

PRQR has been the topic of several research analyst reports. Chardan Capital reaffirmed a "buy" rating and issued a $4.00 price target on shares of ProQR Therapeutics in a research report on Friday, March 14th. Oppenheimer cut their target price on shares of ProQR Therapeutics from $15.00 to $9.00 and set an "outperform" rating for the company in a research note on Tuesday, May 13th. Citigroup upgraded shares of ProQR Therapeutics from a "neutral" rating to a "buy" rating and set a $4.00 target price for the company in a research note on Monday, March 10th. Evercore ISI assumed coverage on shares of ProQR Therapeutics in a report on Tuesday, April 29th. They issued an "outperform" rating and a $5.00 price target for the company. Finally, Cantor Fitzgerald assumed coverage on shares of ProQR Therapeutics in a report on Tuesday, April 29th. They issued an "overweight" rating and a $8.00 price target for the company. One equities research analyst has rated the stock with a sell rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, ProQR Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus target price of $8.00.

ProQR Therapeutics Stock Performance

Shares of ProQR Therapeutics stock traded up $0.05 during trading on Monday, hitting $1.67. The company's stock had a trading volume of 180,013 shares, compared to its average volume of 624,589. The company has a market capitalization of $175.39 million, a PE ratio of -5.22 and a beta of 0.35. ProQR Therapeutics has a 52 week low of $1.07 and a 52 week high of $4.62. The company has a fifty day simple moving average of $1.46 and a two-hundred day simple moving average of $2.33.

ProQR Therapeutics (NASDAQ:PRQR - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.09) by ($0.02). ProQR Therapeutics had a negative net margin of 134.31% and a negative return on equity of 71.58%. The firm had revenue of $4.89 million for the quarter, compared to analysts' expectations of $4.90 million. As a group, analysts predict that ProQR Therapeutics will post -0.31 EPS for the current year.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).